Deals Shaping the Medical Industry, January 2017

11 Jan 2017

• By Steven Muntner, Beth Allan, Maureen Riordan, Deanna Kamienski, and Amanda Micklus

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2016.

Akers Biosciences Inc. licensed Alere Inc.'s First Check Diagnostics LLC exclusive US distribution rights to its rapid cholesterol self-test. (Dec.)

Akers sells the product as Tri-Cholesterol Check but First Check will sell the test under its own First Check brand. The product can determine total and high density lipoprotein cholesterol levels and provide an estimate of low density lipoprotein levels with results in just five minutes

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

07 May 2025

• By David Wild

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

Dealmaking Quarterly Statistics, Q1 2025

05 May 2025

• By Deanna Kamienski and Maureen Riordan

During Q1, biopharma M&A deal value reached $38.4bn and drew in $60.8bn in potential deal value from alliances. Device company M&A values reached $8.7bn.